Professor Sarah Danson is the NIHR CRN National Specialty Lead for Early Phase Cancer Research and chairs the Early Phase Leads Group. The main aim of this role is to improve equity of access to early phase trials. If you would like to get in touch with this group please contact email@example.com
Sarah is a Medical Oncologist specialising in the treatment of melanoma, lung cancer and the early clinical assessment of new anticancer agents. She was a Specialist Registrar in Medical Oncology and a CRUK Clinical Research Fellow in Pharmacology at The Christie Hospital, Manchester before moving to work for Weston Park Hospital and Sheffield University in 2006. Sarah was a member of the CRUK New Agents Committee from 2009-16 and currently sits on the NCRI Skin Cancer Clinical Studies Group and the EORTC (European Organisation for Research and Treatment of Cancer) Lung Cancer and Melanoma Groups. She has been Sheffield ECMC (Experimental Cancer Medicine Centre) Lead since 2016.